SCHEMBL698426

SCHEMBL698426

C#CCON1C(=O)c2ccccc2C1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.56
ALDH1A1 P00352 5/20 0.53
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
CYP1A2 P05177 2/20 0.49
MAPT P10636 2/20 0.49
CYP2C9 P11712 1/20 0.49
ATM Q13315 1/20 0.46
HTT P42858 1/20 0.45
RECQL P46063 1/20 0.44
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
CA12 O43570 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9066846 0.84 GAA (0.49) GAAALDH1A1KMT2AMEN1CYP1A2
SCHEMBL31366901 0.81 GAA (0.62) GAAALDH1A1KMT2AMEN1CYP1A2
SCHEMBL3755047 0.81 GAA (0.56) GAAALDH1A1KMT2AMEN1CYP1A2
SCHEMBL13545621 0.79 GAA (0.69) GAAALDH1A1KMT2AMEN1CYP1A2
SCHEMBL20546987 0.79 GAA (0.59) GAAALDH1A1KMT2AMEN1CYP1A2
SCHEMBL19615818 0.78 MEN1 (0.58) GAAALDH1A1KMT2AMEN1CYP1A2
SCHEMBL31366887 0.78 GAA (0.53) GAAALDH1A1KMT2AMEN1CYP1A2
SCHEMBL6876956 0.78 GAA (0.57) GAAALDH1A1KMT2AMEN1CYP1A2
SCHEMBL22326350 0.77 GAA (0.88) GAAALDH1A1KMT2AMEN1CYP1A2
SCHEMBL17650674 0.75 GAA (0.64) GAAALDH1A1KMT2AMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115820808-A Homogeneous phase fluorescence quantitative detection method for base lacking site in genome DNA sequence 北京大学 2023-03-21 CN claimed
US-7109377-B2 Synthesis of combinatorial libraries of compounds reminiscent of natural products PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2006-09-19 US claimed
US-20030082830-A1 Synthesis of combinatorial libraries of compounds reminiscent of natural products NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-05-01 US claimed
US-6448443-B1 GENERATED FROM DIVERSIFIABLE SCAFFOLDS SYNTHESIZED FROM THE PYRIDINE-BASED TEMPLATE ISONICOTINAMIDE; ALSO PROVIDES A NOVEL ORTHO-NITROBENZYL PHOTOLINKER; SYNTHESIZED FROM A SHIKIMIC ACID BASED EPOXYOL TEMPLATE PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2002-09-10 US claimed
WO-2000006525-A9 SYNTHESIS OF COMBINATORIAL LIBRARIES OF COMPOUNDS REMINISCENT OF NATURAL PRODUCTS HARVARD COLLEGE (US) 2000-04-20 WO claimed
WO-2000006525-A2 SYNTHESIS OF COMBINATORIAL LIBRARIES OF COMPOUNDS REMINISCENT OF NATURAL PRODUCTS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2000-02-10 WO claimed
US-20230302150-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF AMBRX, INC. (US) 2023-09-28 US disclosed
US-20230302150-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF AMBRX, INC. (US) 2023-09-28 US disclosed
EP-4217412-A1 WASTE MITIGATION METHODS AND MATERIALS Finite Research Ltd (GB) 2023-08-02 EP disclosed
CN-116457023-A antibody-TLR agonist conjugates, methods and uses thereof AMBRX公司 2023-07-18 CN disclosed
CN-115820808-A Homogeneous phase fluorescence quantitative detection method for base lacking site in genome DNA sequence 北京大学 2023-03-21 CN disclosed
CN-115353667-A Method and material for reducing waste 李蓁蓁 2022-11-18 CN disclosed
WO-2022023916-A1 WASTE MITIGATION METHODS AND MATERIALS LI, Zhenzhen (CN) 2022-02-03 WO disclosed
EP-0818455-A1 PYRAZOLE DERIVATIVES IDEMITSU KOSAN COMPANY LIMITED (JP) 1998-01-14 EP disclosed
US-5489595-A TREATING RHEUMATOID ARTHRITIS AMERICAN HOME PRODUCTS CORPORATION (US) 1996-02-06 US disclosed
US-5489680-A IMMUNOSUPPRESSIVE, ANTIINFLAMMATORY, ANTIFUNGAL, ANTITUMORAGENT AMERICAN HOME PRODUCTS CORPORATION (US) 1996-02-06 US disclosed
US-5488054-A TREATMENT OF RESTENOSIS AMERICAN HOME PRODUCTS CORPORATION (US) 1996-01-30 US disclosed
US-5484791-A TREATING PULMONARY INFLAMMATION AMERICAN HOME PRODUCTS CORPORATION 1996-01-16 US disclosed
US-5484790-A IMMUNOSUPPRESSANT IN TRANSPLANTS OR GRAFTS AMERICAN HOME PRODUCTS CORPORATION (US) 1996-01-16 US disclosed
US-4584318-A FOR AGRICULTURAL CROPS FMC CORPORATION (US) 1986-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230302150-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF TLR3, TLR1, TLR9 GAA 1473/4885ALDH1A1 2172/4885KMT2A 1152/4885
US-20030082830-A1 Synthesis of combinatorial libraries of compounds reminiscent of natural products TKFC, NISCH, PTGIS GAA 3302/4885ALDH1A1 568/4885KMT2A 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.